nice u-turns on omalizumab for asthma

PharmacoEconomics & Outcomes News 674 - 23 Mar 2013 NICE U-turns on omalizumab for asthma In final draft guidance, the UK NICE has decided to recommend the use of omalizumab [Xolair] as add-on therapy in adults with severe, persistent allergic asthma, reversing its decision in November 2012 not to recommend the treatment. * As a result of the manufacturer making omalizumab available via a patient access scheme, the Appraisal Committee has now estimated that the most plausible incremental cost-effectiveness ratio is £23 200 per QALY gained for the combined population of adults, adolescents and children with persistent allergic asthma. The Committee also acknowledged the health- related QOL benefits of reducing dependence on oral corticosteroids and was persuaded that the inclusion of these additional benefits would be sufficient to make omalizumab a cost-effective treatment. This appraisal of omalizumab is a review of NICE technology appraisal guidance 133 (omalizumab for severe persistent allergic asthma in adults, 2007) and NICE technology appraisal guidance 201 (omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years, 2011) – TA 133 recommended omalizumab for adults, and TA 201 did not recommend it for use in children. * see PharmacoEconomics & Outcomes News 667 p14; 801085622 NICE. NICE says yes to treatment for asthma in final draft guidance. Media Release : 7 Mar 2013. Available from: URL: http://www.nice.org.uk 809147156 1 PharmacoEconomics & Outcomes News 23 Mar 2013 No. 674 1173-5503/10/0674-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: kevin-j-s

Post on 23-Dec-2016

219 views

Category:

Documents

6 download

Report

Download

Embed Size (px):

TRANSCRIPT

PharmacoEconomics & Outcomes News 674 - 23 Mar 2013

NICE U-turns on omalizumab forasthma

In final draft guidance, the UK NICE has decided torecommend the use of omalizumab [Xolair] as add-ontherapy in adults with severe, persistent allergic asthma,reversing its decision in November 2012 not torecommend the treatment.*

As a result of the manufacturer making omalizumabavailable via a patient access scheme, the AppraisalCommittee has now estimated that the most plausibleincremental cost-effectiveness ratio is £23 200 perQALY gained for the combined population of adults,adolescents and children with persistent allergicasthma. The Committee also acknowledged the health-related QOL benefits of reducing dependence on oralcorticosteroids and was persuaded that the inclusion ofthese additional benefits would be sufficient to makeomalizumab a cost-effective treatment.

This appraisal of omalizumab is a review of NICEtechnology appraisal guidance 133 (omalizumab forsevere persistent allergic asthma in adults, 2007) andNICE technology appraisal guidance 201 (omalizumabfor the treatment of severe persistent allergic asthma inchildren aged 6 to 11 years, 2011) – TA 133recommended omalizumab for adults, and TA 201 didnot recommend it for use in children.* see PharmacoEconomics & Outcomes News 667 p14; 801085622

NICE. NICE says yes to treatment for asthma in final draft guidance. MediaRelease : 7 Mar 2013. Available from: URL: http://www.nice.org.uk 809147156

Omalizumab en Asma severa: ejemplo de medicación de alto

Eficacia de Omalizumab en pacientes con asma bronquial …repositorio.ucsg.edu.ec/bitstream/3317/640/1/T-UCSG-PRE... · 2018. 3. 20. · Palabras Clave: Asma persistente, omalizumab,

Omalizumab Fact Sheet - VelaLabs...Omalizumab – Fact Sheet Molecule Omalizumab (Xolair®) is a recombinant humanized IgG1 kappa monoclonal antibody, which binds to free human immunoglobulin

The real world effect of omalizumab add on therapy for ... · mab in the treatment of patients with moderate-to-severe allergic asthma (the ASTERIX Observational study). The primary

XOLAIR (OMALIZUMAB) - UHCprovider.com Home · Xolair® (Omalizumab) Page 2 of 12 UnitedHealthcare Commercial Medical Benefit Drug Policy Effective 03/01/2019 Proprietary Information

Attachment: Product Information for Omalizumab · Web viewAttachment 1: AusPAR - Xolair – omalizumab – Novartis Pharmaceuticals Australia Pty Ltd PM-2019-05980-1-5 FINAL 15 April

Subject: Xolair (Omalizumab)for Allergic Asthma …...• July 2016: FDA Approves Xolair (omalizumab) for allergic asthma in children placing Xolair as the only biologic for children

Omalizumab for previously treated chronic spontaneous

Inhaler technique for people with asthma or COPD · severe asthma being considered for specialised medicines such as omalizumab, inhaler technique must be checked and documented

Omalizumab as a Succesfull Therapy in Normocomplementemic

Biological therapy-associated adverse reactions in asthma ......Nos casos do omalizumab e do mepolizumab, a grande maioria dos pacientes era do sexo feminino (75.6% e 90.0%, respectivamente)